Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

TB Drug Headed Toward Accelerated Approval: Another Wrinkle for Priority Review Vouchers

This article was originally published in RPM Report

Executive Summary

A positive advisory committee for Janssen’s bedaquiline means the second priority review voucher is probably on its way. And it would be the first for an accelerated approval.

You may also be interested in...



Janssen Plans Tiered Pricing For Sirturo In India; Will Work With Government Agencies For Right Use

The TB treatment will be brought to India with a tiered-pricing mechanism, but Janssen says it will work with partners to ensure appropriate use in a country with the highest population of MDR-TB patients.

Janssen Plans Tiered Pricing For Sirturo In India; Will Work With Government Agencies For Right Use

The TB treatment will be brought to India with a tiered-pricing mechanism, but Janssen says it will work with partners to ensure appropriate use in a country with the highest population of MDR-TB patients.

Market Access Strategies: Pending Approvals, J&J Plans Cautious Steps For Access To Anti-TB Drug Bedaquiline

In an interview, Janssen Chairman Paul Stoffels discusses market access issues related to bedaquiline and J&J’s recent decision to free up patents on its HIV therapy Prezista.

Related Content

Topics

UsernamePublicRestriction

Register

LL043624

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel